微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Follicular Lymphoma
Follicular Lymphoma

消化

关键词消化 疾病 非霍奇金淋巴瘤

词汇介绍

拓展阅读

解析

follicular  [fə'lɪkjəlɚ]

释义   adj. 滤泡的;卵泡的;小囊的

例句   Objective:To apply in vitro maturation (IVM) to poor responding of ovary and retardation of follicular development during conventional in vitro fertilization (IVF) cycle. 目的:探讨利用未成熟卵体外成熟技术治疗卵巢反应不良和卵泡发育迟缓周期的可能性。

 

lymphoma 英 [lɪmˈfəʊmə] 美 [lɪmˈfoʊmə]

释义   n. [肿瘤] 淋巴瘤

复数 lymphomas或lymphomata

例句   Methods:To apply the position plate for position and set-up during the Lymphoma irradiation, and compare the effects with the traditional method.  方法:以恶性淋巴瘤为例,放疗过程中应用定位模板进行定位、复位、摆位,同时和传统的方法进行比较。


概述

滤泡性淋巴瘤(follicular lymphoma,FL)在全世界占非霍奇金淋巴瘤(Non-Hodgkin lymphoma, NHL)的22%。滤泡性淋巴瘤患者一般发病年龄较大,多见于50岁以上的患者。在疾病得到诊断时,病变累及的范围已较广泛,除淋巴结病变外,常有脾脏和骨髓累及。尽管如此,这类患者的中位生存时间仍可达 8~12年,因而,滤泡性淋巴瘤被认为属于惰性淋巴瘤的范畴。约90%的患者具有Bcl-2基因重排。 典型症状滤泡性淋巴瘤最常见的表现是无痛性淋巴结肿大,典型表现为多

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma复制标题

FDG-PET显像检测结外和脾脏受累可预测未经治疗的滤泡性淋巴瘤的不良生存

发表时间:2019-04-21

影响因子:6.1

作者: Frederique St-Pierre

期刊:American Journal of Hematology

Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma (NHL) in the United States. 1,2 FL is considered an indolent lymphoma with an estimated 10-year overall survival (OS) of 80%. 3 Patients > 60 years of age at diagnosis statistically have a similar overall survival (OS) as age and sex-matched normal controls4 Unfortunately, a subset of patients performs poorly despite treatment. 4,5 These patients have been described as “clinically discordant indolent lymphomas.”  6-8 At diagnosis, prognosis may be predicted using standard indices. 9-13 These indices do not reliably predict early therapeutic failure, defined as relapse within two years of treatment with immunochemotherapy (IC). 4,5 Conversely, patients who achieve event-free survival (EFS) at 24 months (EFS24) have no added mortality beyond the background population. 4,14 We currently lack full understanding of the factors contributing to this discrepancy in outcomes15 and there is a need to better identify these high-risk patients at diagnosis to potentially guide therapeutic decisions.

译文

滤泡性淋巴瘤(FL)是美国第二大最常见的非霍奇金淋巴瘤(NHL)。 1,2 FL被认为是惰性淋巴瘤,估计10年总生存率(OS)为80%。 3确诊时年龄> 60岁的患者的总体生存率(OS)与年龄和性别匹配的正常对照者相似[4]。不幸的是,尽管进行了治疗,但仍有一部分患者的表现较差。 4,5这些患者被描述为“临床不一致的惰性淋巴瘤”。6-8在诊断时,可使用标准指标预测预后。 9-13这些指标不能可靠地预测早期治疗失败,定义为免疫化学疗法(IC)治疗两年内复发。 4,5相反,在24个月内达到无事件生存(EFS)的患者(EFS24)在背景人群之外没有增加的死亡率。 4,14我们目前对导致结局差异15的因素尚缺乏充分的了解,因此有必要在诊断时更好地识别这些高危患者,以潜在地指导治疗决策。 16